|Bid||85.95 x 100|
|Ask||90.95 x 100|
|Day's Range||87.65 - 88.65|
|52 Week Range||73.45 - 102.49|
|PE Ratio (TTM)||-26.21|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||112.95|
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
A deal with Pfizer, coupled with some likely short-seller covering, has shares headed higher for the second day in a row.
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.